

## Supplementary Materials

**Supplementary Table S1: Searched keywords table**

#	Search
1	"endocarditis, non infective" [MeSH Terms]
2	"endocarditis" [All Fields]
3	"non infective" [All Fields]
4	2 AND 3
5	"non-infective endocarditis" [All Fields]
6	"non" [All Fields]
7	"bacterial" [All Fields]
8	"thrombotic" [All Fields]
9	6 AND 7 AND 8 AND 2
10	"marantic endocarditis" [All Fields]
11	"marantic" [All Fields]
12	11 AND 2
13	"trousseau" [All Fields] OR "trousseau s" [All Fields])
14	"syndrome" [All Fields] OR "syndromal" [All Fields] OR "syndromally" [All Fields] OR "syndrome" [MeSH Terms] OR "syndrome" [All Fields] OR "syndromes" [All Fields] OR "syndrome s" [All Fields] OR "syndromic" [All Fields] OR "syndroms" [All Fields]
15	13 AND 14
16	"cancer s"[All Fields] OR "cancerated"[All Fields] OR "canceration"[All Fields] OR "cancerization"[All Fields] OR "cancerized"[All Fields] OR "cancerous"[All Fields] OR "neoplasms"[MeSH Terms] OR "neoplasms"[All Fields] OR "cancer"[All Fields] OR "cancers"[All Fields]
17	1 OR 4 OR 9 OR 12 OR 15
18	16 AND 17

**Supplementary Table S2: Quality assessment of the included studies ¶**

	Country	Q1 ¶	Q2	Q3	Q4	Q5	Q6	Q7	Q8
Ahmed 2018(22)	USA	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Alaiti 2015(23)	USA	Yes	Yes	No	Yes	Yes	Unclear	Yes	Yes
Albright 2016(24)	USA	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes
Ali 2012(25)	Australia	Yes	Yes	Yes	Yes	Yes	Unclear	Yes	Yes
Ali 2015(26)	UK	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Arvold 2011(27)	USA	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Ashenhurst 1962(28)	Canada	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Bhardwaj 2016(29)	USA	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Binet 2021(30)	Belgium	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Borowski 2005(31)	Germany	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Chen 2004(32)	USA	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Cheung 2020(33)	USA	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Chisholm 1982(34)	USA	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Clough 2010(35)	UK	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Detremmerie 2017 (36)	Belgium	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Dewey 2014(37)	UK	Yes	Yes	Yes	Yes	Yes	Unclear	Yes	No
Douin 2020(38)	Italy	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes
Elboudwarej 2015(39)	USA	Yes	Yes	Yes	Yes	Yes	Yes	Unclear	No
Fanale 2002(40)	Taiwan	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Farooqui 2021(41)	USA	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Ferreira 2017(42)	Portugal	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Fournier 2019(43)	USA	Yes	Yes	Yes	Yes	Yes	Yes	Unclear	No
Frazer 2005(44)	UK	Yes	Yes	Yes	Yes	Yes	No	No	Yes
Fujimoto 2018(45)	Japan	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No
Garcia 1983(46)	USA	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Glass 1993(47)	USA	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Gray 2021(48)	USA	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Green 1990(49)	Scotland	Yes	Yes	Yes	Yes	No	Yes	No	Yes
Gundersen 2016 (50)	UK	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Harris 2021(51)	New Zealand	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Hofstra 2009(52)	Netherlands	Yes	Yes	Yes	Yes	Yes	Yes	Unclear	No
Holt 2021(53)	Australia	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Ilyas 2021(54)	Rhode Island	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Iranpour 2013(55)	Iran	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Ito 2013(56)	Japan	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Jameson 2009(57)	USA	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

	Country	Q1 ¶	Q2	Q3	Q4	Q5	Q6	Q7	Q8
Joshi 2009(58)	USA	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Julson 2018 (59)	USA	No	No	No	No	No	Yes	Yes	Yes
Kalangos 1997(60)	Switzerland	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Kaneyuki 2017(61)	Japan	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Kanthasamy 2016(62)	UK	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Kaufmann 2020(63)	Austria	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Kearsley 1982(64)	Australia	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Khan 2008 (65)	UK	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Khan 2019(66)	Pakistan	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Kijpaisalratanaa 2020(67)	Thailand	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Kimyai-Asadi 2001(68)	USA	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Kooiker 1976(69)	USA	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Kuipers 2021(70)	Netherlands	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Kurdi 2004 (71)	Canada	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Kwon 2016(72)	Korea	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No
Lal 2003(73)	USA	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Lee 2012 (74)	Australia	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Lee 2014(75)	Korea	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Makhdumi 2021(76)	USA	Yes	Yes	Yes	Yes	Yes	No	Unclear	Yes
Mantovani 2016(77)	Italy	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Marglani 2009(78)	Canada	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Markides 2000(79)	UK	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Martín-Martorell 2007(80)	Spain	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Mitma 2016(81)	USA	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Morimoto 2016 (82)	Japan	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No
Moțățianu 2018(83)	Romania	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Nadkarni 2020 (84)	USA	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No
Nakashima 2012(85)	Japan	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Neilan 2018(86)	USA	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Al Nidawi 2021(87)	Kingdom of Bahrain	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Numnum 2006 (88)	USA	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
O'boyle 1981(89)	Ireland	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Ojeda 1985(90)	Australia	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Okuchi 1997(91)	Japan	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Olney 1979(92)	USA	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Orfanelli 2016(93)	USA	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Oueida 2011(94)	USA	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

	Country	Q1 ¶	Q2	Q3	Q4	Q5	Q6	Q7	Q8
<b>Panicucci 2020 (95)</b>	France	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
<b>Patel 2020(19)</b>	USA	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
<b>Perrone 2020(96)</b>	Italy	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
<b>Piovanelli 2013(97)</b>	Italy	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
<b>Polo 2021(98)</b>	France	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
<b>Ramirez-Escudero Ugalde 2020(99)</b>	Spain	Yes	Yes	Yes	Yes	Yes	No	Unclear	Yes
<b>Randhawa 2020(100)</b>	USA	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes
<b>Royter 2006(101)</b>	USA	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
<b>Sakima 2011(102)</b>	Japan	Yes	Yes	Yes	Yes	Yes	No	Unclear	Yes
<b>Sanchez-Quirós 2020(103)</b>	Spain	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
<b>Sánchez-Enrique 2014(104)</b>	Spain	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
<b>Savarapu 2021(105)</b>	USA	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
<b>Sawai 2018(106)</b>	Japan	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
<b>Scalia 2012(107)</b>	Australia	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
<b>Sekulic 2020(108)</b>	USA	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
<b>Shatila 2014(109)</b>	Lebanon	Yes	Yes	Yes	Yes	Yes	Unclear	Yes	Yes
<b>Shibata 2018(110)</b>	Japan	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
<b>Shoji 2019(111)</b>	USA	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
<b>Shuaib, 1991(112)</b>	Canada	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
<b>Sia 2016(113)</b>	Singapore	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
<b>Singh 2007(114)</b>	USA	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
<b>Smeglin 2008(115)</b>	USA	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
<b>Soga 2018(116)</b>	Japan	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
<b>Spurgeon 2021(117)</b>	UK	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
<b>Starobinska 2018(118)</b>	USA	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
<b>Studdy 1976(119)</b>	UK	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
<b>Sugawara 2021(120)</b>	Japan	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
<b>Suzuki 2002(121)</b>	Japan	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
<b>Tai 2016(122)</b>	Malaysia	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
<b>Takeshita 2018(123)</b>	Japan	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
<b>Tamura 2021(124)</b>	Japan	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
<b>Tiong 2012(125)</b>	New Zealand	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
<b>Tsai 2015 (126)</b>	Taiwan	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
<b>Umeojiako 2019(127)</b>	UK	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
<b>Vaideeswar 1993(128)</b>	India	Yes	Yes	No	No	No	Yes	Yes	Yes
<b>Van Herck 2021(129)</b>	Belgium	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
<b>Vlachostergios 2010(130)</b>	Greece	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

	Country	Q1 ¶	Q2	Q3	Q4	Q5	Q6	Q7	Q8
Wang 2020 (131)	USA	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Washburn 2016(132)	USA	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Wigger 2016(133)	Switzerland	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Wild 2021 (134)	Germany	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Wong 2013(135)	Australia	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Woo 2014(136)	China	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Yagi 2014(137)	Japan	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Yamane 2014(138)	Japan	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Yasutake 2016(139)	Japan	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Yoshii 2014(140)	Japan	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Zhou 2021(141)	Singapore	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

¶ Q1: patient's demographic characteristics, Q2 patient's history and its timeline, Q3 current clinical condition of the patient on presentation, Q4 diagnostic tests or assessment methods and results, Q5 intervention(s) or treatment procedure(s), Q6 post-intervention clinical condition, Q7 adverse events (harms) or unanticipated events, and Q8 takeaway lessons, with each question was answered by either (yes, no, unclear, or not applicable)

**Supplementary Table S3: Different criteria among A) females vs males, and B) marantic first presentation vs known cancer**


		A) females vs males			B) marantic first presentation vs known cancer		
	Level	Female	Male	p	Known cancer	Marantic first presentation	p
<b>n</b>		81	63		42	83	
<b>Antiphospholipid antibodies (%)</b>	No	79(97.5)	62(98.4)	1	42(100.0)	80(96.4)	0.53
	Yes	2(2.5)	1(1.6)		0(0.0)	3(3.6)	
<b>Primary Cancer Organ (%)</b>	Gynecological	23(28.4)	0(0.0)	<0.001	11(26.2)	12(14.5)	0.312
	Lung	18(22.2)	23(36.5)		8(19.0)	23(27.7)	
	Other GIT Cancers	11(13.6)	8(12.7)		6(14.3)	11(13.3)	
	Others	12(14.8)	21(33.3)		12(28.6)	19(22.9)	
	Pancreas	17(21.0)	11(17.5)		5(11.9)	18(21.7)	
<b>Lung vs Other Cancers (%)</b>	Others	63(77.8)	40(63.5)	0.089	34(81.0)	60(72.3)	0.401
	Lung cancer	18(22.2)	23(36.5)		8(19.0)	23(27.7)	
<b>Pathology (%)</b>	Adenocarcinoma	57(70.4)	36(57.1)	0.118	19(45.2)	60(72.3)	0.015
	Hematopoietic	1(1.2)	5(7.9)		4(9.5)	1(1.2)	
	Others	21(25.9)	17(27)		16(38.1)	20(24.1)	
	Sarcoma	0(0.0)	1(1.6)		1(2.4)	0(0.0)	
	SCC	2(2.5)	4(6.3)		2(4.8)	2(2.4)	
<b>Adenocarcinoma vs other pathologies (%)</b>	Other pathologies	24(29.6)	27(42.9)	0.141	23(54.8)	23(27.7)	0.006
	Adenocarcinoma	57(70.4)	36(57.1)		19(45.2)	60(72.3)	
<b>Organ of metastasis (n=97) (%)</b>	Bone	0(0.0)	5(10.6)	0.246	0(0.0)	4(7.4)	0.085
	Brain	1(2.0)	2(4.3)		2(8.0)	1(1.9)	
	Liver	15(30.0)	8(17)		6(24.0)	15(27.8)	
	Lung	4(8.0)	3(6.4)		2(8.0)	4(7.4)	
	Lymph nodes	11(22.0)	11(23.4)		3(12.0)	18(33.3)	

		A) females vs males			B) marantic first presentation vs known cancer		
	Level	Female	Male	p	Known cancer	Marantic first presentation	p
	Multiple	12 (24.0)	13 (27.7)		8 (32.0)	6 (11.1)	
	Others	7 (14.0)	5 (10.6)		4 (16.0)	6 (11.1)	
<b>Metastasis (n=141) (%)</b>	Non- Metastatic	30(37.5)	13(21.7)	0.068	14(35.9)	29(34.9)	1
	Metastatic	50(62.5)	47(78.3)		25(64.1)	54(65.1)	
<b>Marantic presentation before diagnosis of cancer (n=125) (%)</b>	Known cancer case	28(38.4)	14(26.9)	0.254	42 (100.0)	0 (00.0)	-----
	Marantic as a first presentation	45(61.6)	38(73.1)		0 (00.0)	83 (100.0)	
<b>Interval Diagnosis (Months) (mean (SD))</b>		8.25(31.57)	3.45(12.99)	0.345	20.39(44.18)	0.32(1.98)	<0.001
<b>Age (median [IQR])</b>		59.00[49.00,65.00]	61.00[50.00,67.50]	0.166	57.00[49.25,66.00]	61.00[49.50,65.00]	0.708
<b>Sex (%)</b>	F	81(100.0)	0 (00.0)	-----	28(66.7)	45(54.9)	0.285
	M	0 (00.0)	63(100.0)		14(33.3)	37(45.1)	
<b>COPD (n=52) (%)</b>	No	29(96.7)	20(90.9)	0.781	10(90.9)	38(95.0)	1
	Yes	1(3.3)	2(9.1)		1(9.1)	2(5.0)	
<b>Smoke (n=56) (%)</b>	No	26(81.2)	17(70.8)	0.553	9(75.0)	33(76.7)	1
	Yes	6(18.8)	7(29.2)		3(25.0)	10(23.3)	
<b>Diabetes (n=52) (%)</b>	No	25(83.3)	18(81.8)	1	9(81.8)	33(82.5)	1
	Yes	5(16.7)	4(18.2)		2(18.2)	7(17.5)	
<b>Obesity (n=53) (%)</b>	No	30(96.8)	22(100.0)	1	11(91.7)	40(100.0)	0.519
	Yes	1(3.2)	0(0.0)		1(8.3)	0(0.0)	
<b>Dyslipidemia (n=54) (%)</b>	No	25(80.6)	21(91.3)	0.482	9(75.0)	36(87.8)	0.528
	Yes	6(19.4)	2(8.7)		3(25.0)	5(12.2)	
<b>Hypertension (n=56) (%)</b>	No	20(64.5)	16(64.0)	1	8(61.5)	27(64.3)	1
	Yes	11(35.5)	9(36.0)		5(38.5)	15(35.7)	


		A) females vs males			B) marantic first presentation vs known cancer		
	Level	Female	Male	p	Known cancer	Marantic first presentation	p
<b>Embolization event at presentation (n=132) (%)</b>	No	6 (7.9)	9 (16.1)	0.236	8 (19.5)	6 (7.4)	0.093
	Yes	70 (92.1)	47 (83.9)		33 (80.5)	75 (92.6)	
<b>Emboic event after diagnosis (n=125) (%)</b>	No	41 (56.9)	35 (66)	0.399	27 (65.9)	46 (56.8)	0.442
	Yes	31 (43.1)	18 (34)		14 (34.1)	35 (43.2)	
<b>Incidental finding of NBTE (%)</b>	No	76(93.8)	56(88.9)	0.447	36(85.7)	79(95.2)	0.135
	Yes	5(6.2)	7(11.1)		6(14.3)	4(4.8)	
<b>Postmortem diagnosis of NBTE (%)</b>	No	55(67.9)	40(63.5)	0.706	31(73.8)	63(75.9)	0.971
	Yes	26(32.1)	23(36.5)		11(26.2)	20(24.1)	
<b>Position of vegetation (n=132) (%)</b>	aortic	28(37.8)	20(34.5)	0.229	11(30.6)	25(32.5)	0.888
	Left atrium	0(0.0)	1(1.7)		0(0.0)	1(1.3)	
	mitral	31(41.9)	31(53.4)		19(52.8)	37(48.1)	
	Multiple	15(20.3)	6(10.3)		6(16.7)	14(18.2)	
<b>Valve insufficiency (n=89) (%)</b>	No	16(30.2)	12(33.3)	0.935	9(28.1)	19(33.3)	0.787
	yes	37(69.8)	24(66.7)		23(71.9)	38(66.7)	
<b>Valve stenosis (n=90) (%)</b>	No	48(90.6)	33(89.2)	1	28(87.5)	53(91.4)	0.826
	Yes	5(9.4)	4(10.8)		4(12.5)	5(8.6)	
<b>Underwent Intervention (%)</b>	No	68(84.0)	55(87.3)	0.744	36(85.7)	68(81.9)	0.778
	Yes	13(16.0)	8(12.7)		6(14.3)	15(18.1)	
<b>Type of surgery (%)</b>	Excision of vegetation	4(4.9)	1(1.6)	0.551	3(7.1)	2(2.4)	0.203
	None	68(84.0)	55(87.3)		36(85.7)	68(81.9)	
	replacement	9(11.1)	7(11.1)		3(7.1)	13(15.7)	

		A) females vs males			B) marantic first presentation vs known cancer		
	Level	Female	Male	p	Known cancer	Marantic first presentation	p
<b>Presenting symptoms (n=139) (%)</b>	Cardiological	3 (3.9)	3 (5.5)	0.552	2 (5.1)	3 (3.6)	0.582
	Neurological	60 (77.9)	36 (65.5)		25 (64.1)	63 (75.9)	
	Others	4 (5.2)	3 (5.5)		3 (7.7)	4 (4.8)	
	Respiratory	6 (7.8)	7 (12.7)		6 (15.4)	6 (7.2)	
	Vascular	4 (5.2)	6 (10.9)		3 (7.7)	7 (8.4)	
<b>Death (144) (%)</b>	No	25(31.2)	21 (33.3)	1	12(29.3)	32(39.0)	0.387
	Yes	55(68.8)	42 (66.7)		29(70.7)	50(61.0)	
<b>Time to death(days) (median [IQR])</b>		37.94[7.00,122.50]	33.60[7.00,150.00]	0.873	16.80[3.50,56.00]	16.80[0.00,45.64]	0.579

**Supplementary Figure S1: PRISMA flowchart of included studies (N=121)/cases (N=144)**



**Supplementary FIGURE S2: Kaplan Meier curves with Estimated survival time among (A) Entire cohort, (B) females vs ales, (C) lung vs others, and (D) marantic 1st presentation vs known cancer, (E) intervention vs no-intervention, (F) metastatic vs non-metastatic cases**



**Supplementary Figure S3.** Number of cases reported per each country

